View Item 

Show simple item record

Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling
dc.contributor.authorGajewski, Byron J.
dc.contributor.authorBerry, Scott M.
dc.contributor.authorBarsan, William G.
dc.contributor.authorSilbergleit, Robert
dc.contributor.authorMeurer, William J.
dc.contributor.authorMartin, Renee
dc.contributor.authorRockswold, Gaylan L.
dc.date.accessioned2016-10-17T21:19:40Z
dc.date.available2017-11-01T15:31:29Zen
dc.date.issued2016-09
dc.identifier.citationGajewski, Byron J.; Berry, Scott M.; Barsan, William G.; Silbergleit, Robert; Meurer, William J.; Martin, Renee; Rockswold, Gaylan L. (2016). "Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling." Pharmaceutical Statistics 15(5): 396-404.
dc.identifier.issn1539-1604
dc.identifier.issn1539-1612
dc.identifier.urihttps://hdl.handle.net/2027.42/134231
dc.publisherOxford University Press
dc.publisherWiley Periodicals, Inc.
dc.subject.othermultiple factors
dc.subject.otherphase II clinical trial
dc.subject.otherBayesian adaptive design
dc.titleHyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134231/1/pst1755_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134231/2/pst1755.pdf
dc.identifier.doi10.1002/pst.1755
dc.identifier.sourcePharmaceutical Statistics
dc.identifier.citedreferenceFinkelstein E, Corso P, Miller T. The Incidence and Economic Burden of Injuries in the United States. Oxford University Press: New York, 2006.
dc.identifier.citedreferenceLin K, Niu K, Tsai K, Kuo J, Wang L, Wang L, Chio C, Chang C. Attenuating inflammation but stimulating both angiogenesis and neurogenesis using hyperbaric oxygen in rats with traumatic brain injury. Journal Trauma. 2012; 72 ( 3 ): 650 – 659.
dc.identifier.citedreferenceKim MO, Liu C, Hu F, Lee JJ. Outcome‐adaptive randomization for a delayed outcome with a short‐term predictor: imputation‐based designs. Statistics in Medicine. 2014; 33 ( 23 ): 4029 – 42.
dc.identifier.citedreferenceCai C, Liuc S, Yuanc Y. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine. 2014; 33 ( 23 ): 4017 – 4028.
dc.identifier.citedreferenceBerry SM, Spinelli W, Littman GS, Liang JZ, Fardipour P, Berry DA, Lewis RL, Krams M. A Bayesian dose‐finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clinical Trials. 2010; 7: 121 – 135.
dc.identifier.citedreferenceRockswold SB, Rockswold GL, Zaun DA, Liu J. A prospective, randomized phase II clinical trial to evaluate the effect of combined hyperbaric and normobaric hyperoxia on cerebral metabolism, intracranial pressure, oxygen toxicity, and clinical outcome in severe traumatic brain injury. Journal Neurosurg. 2013; 118 ( 6 ): 1317 – 1328.
dc.identifier.citedreferenceYuan Y, Yin G. Sequential continual reassessment method for two‐dimensional dose‐finding. Statistics in Medicine. 2008; 27: 5664 – 5678.
dc.identifier.citedreferenceLunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000; 10: 325 – 337.
dc.identifier.citedreferenceCore Team R. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2013. Available at: http://www.R-project.org/ (accessed 26.05.2016).
dc.identifier.citedreferenceBerry S, Sanil A. FACTS™ Dose Finding: Single Endpoint Engine Specification. Tessela: Newton, MA, 2010.
dc.identifier.citedreferenceMeurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? Journal of the American Medical Association. 2012; 307 ( 22 ): 2377 – 2378.
dc.identifier.citedreferenceJin IH, Huo L, Yin G, Yuan Y. Phase I trial design for drug combinations with Bayesian model averaging. Pharmaceutical Statistics. 2015; 14: 108 – 119.
dc.identifier.citedreferenceThall PF, Millikan RE, Mueller P, Lee SJ. Dose‐finding with two agents in phase I oncology trials. Biometrics. 2003; 59: 487 – 496.
dc.identifier.citedreferenceBerry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials. CRC Press: New York, 2011.
dc.identifier.citedreferenceConnor JT, Elm JJ, Broglio KR, Investigators ADAPT‐IT. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. Journal of Clinical Epidemiology. 2013; 66 ( 8S ): S130 – 137.
dc.identifier.citedreferenceWang K, Ivanova A. Two‐dimensional dose‐finding in discrete dose space. Biometrics. 2005; 61: 217 – 222.
dc.identifier.citedreferenceLee JJ, Chu CT. Bayesian clinical trials in action. Statistics in Medicine. 2012; 31 ( 25 ): 2955 – 2972.
dc.identifier.citedreferenceWick J, Berry SM, Yeh H, Choi W, Pacheco CM, Daley C, Gajewski BJ. A novel evaluation of optimality for randomized controlled trials. Journal of Biopharmaceutical Statistics. (in press).
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pst1755_am.pdf
Size:
687.1KB
Format:
PDF
View/Open
Name:
pst1755.pdf
Size:
725.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.